Yungjin Pharm

영진약품 · 003520

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$172.2M (₩237.6B)

Overview

Yungjin Pharm is a South Korean pharmaceutical company that develops and supplies medicines for human health.

Its products reach patients and healthcare providers through the domestic pharmaceutical market. The company is listed on KOSPI, Korea's main stock exchange. The filing does not provide sufficient detail to identify a single dominant structural fact about its business model or product mix.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$184.2M

▲ +0.9% YoY

Operating profit · FY2025

US$2.5M

▼ −60.8% YoY

Net income · FY2025

−US$165K

Turned to loss

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$170.2M(₩234.9B)	US$182.6M(₩252B)	US$184.2M(₩254.3B)
Operating profit	US$2.3M(₩3.1B)	US$6.3M(₩8.7B)	US$2.5M(₩3.4B)
Net income	−US$2.8M(−₩3.9B)	US$893.3K(₩1.2B)	−US$165K(−₩227.7M)

Revenue

FY2023US$170.2M
FY2024US$182.6M
FY2025US$184.2M

Operating profit

FY2023US$2.3M
FY2024US$6.3M
FY2025US$2.5M

Net income

FY2023−US$2.8M
FY2024US$893.3K
FY2025−US$165K

Key ratios (FY2025)

ROE

-0.3%

Debt/Eq

186.9%

Op. margin

1.3%

Net margin

-0.1%

Rev. YoY

▲ +0.9%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?